Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Fosun Pharma Announces 2025Q3 Financial Results 2025-10-28 20:11
Fosun Pharma Announces 2025 Interim Results 2025-08-26 20:42
Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million 2025-08-12 09:36
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology 2025-06-16 21:03
Fosun Pharma Announces 2024 Annual Results 2025-03-26 10:29
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets) 2025-02-26 18:33
Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation 2025-02-17 16:22
Fosun Pharma Announces 2024Q3 Financial Results 2024-10-30 10:41
Fosun Pharma Announces 2024 Interim Results 2024-08-28 18:10
Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa 2024-04-26 12:39
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs 2023-12-14 17:00
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure 2023-08-30 10:53
Fosun Pharma Participates in 2023 BIO International Convention to Demonstrate its Global Innovation Capabilities 2023-06-06 22:15
Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa 2023-06-06 19:52
Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements 2023-05-10 22:57
Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative 2023-04-26 22:32
Fosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public 2023-03-29 14:06
Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement 2023-03-28 16:20
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US 2023-01-07 17:29
Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents 2022-11-28 22:59
1 2